KRAS and cancer: The KRAS G12D mutation, which accounts for approximately 30% of all KRAS mutations in pancreatic cancer, drives expression of ICAM1 by acinar cells in vivo a mouse model, attracting macrophages to accelerate formation of pre-cancer pancreatic lesions [74].